

Cervical Cancer Task Force Regular Meeting

**October 29, 2015
Minutes**

Attending Task Force Members (8):

Dr. Jennifer Dillaha, Dr. Charity Smith, Michelle Murtha, Louise Scott

Dr. Paul Green, Amy Daniel, Dr. Nancy Andrews-Collins and Dr. Cygnet Schroeder-Bise (via phone conference)

Absent Task Force Members (3):

Beth Ingram, and Christy McCreight, Dr. Renee Montgomery.

Arkansas Cancer Coalition (ACC):

Trena Mitchell

Arkansas Department of Health (ADH):

Linda Faulkner

Brandy Sutphin

I. Call to order:

Dr. Jennifer Dillaha, Task Force Chair, called the meeting to order at 4:34 p.m.

A. Welcome and Introductions:

Dr. Dillaha welcomed attendees and asked members and staff to introduce themselves.

B. Comments from the Public:

There were no comments from the public.

II. Task Force Business

A. Approval of Minutes (from January 8, 2015)

- Taskforce members reviewed the minutes from the January 8th meeting. No changes were requested. There was a motion to approve the minutes and a unanimous consent that the minutes be approved.

B. Update on ACIP recommendations for HPV vaccination

- Three vaccines are approved by the FDA to prevent HPV infection: Gardasil, Gardasil 9, and Cervarix. All three vaccines prevent infections with HPV types 16 and 18, two high-risk HPVs that cause about 70 percent of cervical cancers and an even higher percentage of some of the other HPV-associated cancers.

- The FDA has approved Gardasil and Gardasil 9 for use in females ages 9 through 26 for the prevention of HPV-caused cervical, vulvar, vaginal, and anal cancers; precancerous cervical, vulvar, vaginal, and anal lesions; and genital warts. Gardasil and Gardasil 9 are also approved for use in males for the prevention of HPV-caused anal cancer, precancerous anal lesions, and genital warts. Gardasil is approved for use in males ages 9 through 26, and Gardasil 9 is approved for use in males ages 9 through 15.
- The Cervarix vaccine is produced by GlaxoSmithKline (GSK). It targets two HPV types—16 and 18—and is called a bivalent vaccine. The FDA has approved Cervarix for use in females ages 9 through 25 for the prevention of cervical cancer caused by HPV.
 - Comments on vaccines:
 - Dr. Andrews-Collins asked if there is a cost difference between the 4-valent and 9-valent because some AR physicians are unable to stock the vaccine.
 - Dr. Dillaha mentioned that the 9-valent is a bit more expensive than the 4-valent (approximate \$30) and that there is a childhood immunization taskforce to assist with changing the payment (reimbursement) environment so that AR physicians can offer the vaccination.
 - Dr. Andrews-Collins asked if there is a recommendation to re-vaccinate those who have received the 4-valent vaccine.
 - Dr. Dillaha said that there is no recommendation to re-vaccinate anyone who has received the 4-valent vaccine.

C. Announce CCTF Reappointments

- Linda Faulker of ADH BreastCare program announced that Amy Daniels of AR Academy of Family Practitioners and Louise Scott of the AR Minority Health Commission have been reappointed to serve on the CCTF. Amy Daniels and Louise Scotts appointments started on August 28, 2014 and will run through August 28, 2018. Amy and Louise have received their letters from ADH. Terms were staggered so that everyone will not roll off the CCTF at the same time.

D. Update on the Arkansas Cancer Summit Cervical Cancer Breakout Session

- The purpose of the breakout session was to get input from a broad range of stakeholders to update the AR Cancer Plan. Ovarian Cancer was not addressed because there is not much movement in AR on

Ovarian Cancer. Participants developed strategies around HPV vaccinations. Input during the breakout session was considered for the final AR Cancer Plan.

- ADH is also developing a strategic plan for immunizations in AR.

E. Draft of the Arkansas Cancer Plan, Third Edition

- ACC reviewed the CCTF recommendations for the AR Cancer Plan Cervical Cancer Chapter. All sources and citations have been verified. The Cervical Cancer Chapter has been formatted into APA style. A final draft was submitted to ADH in September. ACC is waiting on feedback from ADH.

F. Scheduling of Next Task Force Meeting

- Dr. Dillaha suggested that we have a sub-group focused on quality measures. Linda Faulkner will ask Joanne Jones with the BreastCare program what quality measures are being used in Arkansas and give an update at the next meeting.
- Future meeting dates are:
 1. Thursday, January 21, 2016
 2. Thursday, April 21, 2016
 3. Thursday, July 21, 2016
 4. Thursday, October 20, 2016

III. Closing

Dr. Dillaha closed the formal meeting at 5:27 pm